BioInsights - BioInsights

IMMUNO-ONCOLOGY INSIGHTS

July 2021 Issue

Vol 2 issue 4

Immuno-Oncology Insights Vol 2 issue 4
View

Latest Articles

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

29 March 2022
Application Note
T cell immunotherapy: addressing toxicity issues in a rapidly commercializing field

T cell immunotherapy: addressing toxicity issues in a rapidly commercializing field

15 January 2021
Interview
Necessity for next-generation quality assessment of CAR T cell manufacturing and advanced therapy guidance

Necessity for next-generation quality assessment of CAR T cell manufacturing and advanced therapy guidance

B Seliger, K Reiche, C Massa et al.
15 December 2020
Commentary
Model-based dose escalation designs used in early-phase 1 trials to assess safety and tolerability of immuno-oncology therapies

Model-based dose escalation designs used in early-phase 1 trials to assess safety and tolerability of immuno-oncology therapies

15 December 2020
Commentary
Clinical development strategy of immunotherapy combination

Clinical development strategy of immunotherapy combination

T Enokida, C Carr, N Bhardwaj
10 December 2020
Expert Insight
Early use of tocilizumab and lead-in dose to mitigate flotetuzumab associated infusion-related reaction/cytokine release reaction in patients with relapsed or refractory acute myeloid leukemia

Early use of tocilizumab and lead-in dose to mitigate flotetuzumab associated infusion-related reaction/cytokine release reaction in patients with relapsed or refractory acute myeloid leukemia

K Jacobs, O Bakkacha, P Patel et al.
9 December 2020
Short Communication
The rise of next-generation T-cell engagers with better safety and efficacy

The rise of next-generation T-cell engagers with better safety and efficacy

8 December 2020
Commentary
Future pathways towards improving clinical safety and efficacy of immunotherapy agents in melanoma

Future pathways towards improving clinical safety and efficacy of immunotherapy agents in melanoma

Paolo Ascierto
8 December 2020
Interview
Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics

Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics

I Roodink, P Ott, N Senutovitch
1 December 2020
Innovator Insight

Channel content